The Value of Patient Education

Week in Review: The Value of Patient Education

12.06.13 | By Kaelan Hollon

It’s a basic tenant of our industry: the well-being of patients is one of the most important pillars of the biopharmaceutical industry. Whether in the creation of new medications or updating information about current medicine, our industry strives to educate patients safely and transparently on the status of treatments that could change their lives. As we celebrate the life of Nelson Mandela, one of the world’s greatest leaders, we’re reminded of one of his most well-known remarks: "Education is the most powerful weapon which you can use to change the world."

If you have been keeping up with us on The Catalyst you may have read about our commitment with member companies and the European Federation of Pharmaceutical Industries and Associations (EFPIA) to enhance responsible clinical data sharing through the Principles for Responsible Clinical Trial Data Sharing: Our Commitment to Patients and Researchers. With an implementation date right around the corner, we cannot stress enough how important clinical trials can be to the creation of new medications for patients. Through these commitments we hope to ensure that clinical trial data is shared in a responsible and safe manner in order to continue this important step in developing new and effective treatments for patients.

Thanks to many clinical trials conducted around the nation new medicines can make their way through the development pipeline and hopefully become available to patients. This week we released out latest Medicines in Development report on infectious diseases. With nearly 394 medicines in development for infectious diseases including HIV, malaria and Hepatitis C, today’s biopharmaceutical researchers have made great strides and continue to find innovation solutions to help treat and eradicate these diseases. Read the full report on infectious diseases here to learn more about the future of treating infectious diseases to improve patients’ lives.

Patient education is key to fighting the battle against fake medicines that may impact their health, so this week’s launch of a new campaign to put an end to counterfeit medicines was particularly notable. Fight the Fakes  hopes to tackle the world’s counterfeit medication distribution which is currently a $75 billion to $200 billion per year business and can account for 10-30 percent of fake medicines around the globe. Learn more about the campaign at http://fightthefakes.org/ and join the fight by spreading the word about the dangers of counterfeit medicines.

As a patient or advocate, we hope you’re learning and sharing all that is in the pipeline to help treat and protect Americans. Be sure to check back for more information on the work we are doing to continually improve patients’ health, and remember to share your thoughts and comments with us.

Comments

Hide Comments

More On PhRMA — powered by PhRMApedia